Business Context and Reporting Period
This Form 8-K Current Report was filed by Rhythm Pharmaceuticals, Inc. on March 16, 2021, covering events occurring on March 11, 2021. The filing addresses Item 5.02 regarding the appointment of a new principal officer and the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of William T. Roberts as Chief Accounting Officer and Principal Accounting Officer, effective on or about March 29, 2021. He succeeds Hunter Smith in the Principal Accounting Officer role, while Mr. Smith retains his positions as Chief Financial Officer and Treasurer.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Mr. Roberts:
- Base Salary: $285,000 annually.
- Discretionary Bonus: Eligible for up to 30% of annual base salary based on performance goals.
- Equity Award: 10,000 restricted stock units and 20,000 stock options under the 2017 Equity Incentive Plan.
- Severance: Three months of continued base salary payments if terminated without cause or if he resigns for good reason, subject to executing a release of claims.
Mr. Roberts will also enter into the Company's standard indemnification agreement for directors and officers.
Investor Verification Checklist
- Confirm the exact commencement date of Mr. Roberts' employment (expected on or about March 29, 2021).
- Review the specific performance goals tied to the 30% discretionary bonus in future filings or proxy statements.
- Verify the vesting schedule for the 10,000 RSUs and 20,000 stock options granted.
- Monitor future filings for any changes to the Principal Accounting Officer role or further executive departures.